title: Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats.
abstract: The available data on the role of the L-arginine/nitric oxide (NO) pathway in the genesis of hypertension in spontaneously hypertensive rats (SHR) are limited and contradictory. In an attempt to address this issue, male SHR were studied during the early phase of evolution of hypertension (age 8 to 12 weeks) to distinguish the primary changes of NO metabolism from those caused by advanced hypertension, vasculopathy, and aging late in the course of the disease. A group of age-matched male Wistar-Kyoto rats (WKY) served as controls. The SHR exhibited a marked rise in arterial blood pressure and a significant increase in urinary excretion and plasma concentration of NO metabolites (nitrite/nitrate [NOx]). Likewise, the SHR showed a significant elevation of thoracic aorta NO synthase (NOS) activity coupled with significant increases of kidney, aorta, inducible NOS (iNOS), and endothelial NOS (eNOS) proteins. In an attempt to determine whether the enhanced L-arginine/NO pathway is a consequence of hypertension, studies were repeated using 3-week-old animals before the onset of hypertension. The study revealed significant increases in urinary NOx excretion as well as vascular eNOS and renal iNOS proteins. In conclusion, the L-arginine/NO pathway is upregulated in young SHR both before and after the onset of hypertension. Thus, development of hypertension is not due to a primary impairment of NO production in SHR. On the contrary, NO production is increased in young SHR both before and after the onset of hypertension.
authors.affiliation: Division of Nephrology, Department of Medicine, University of California at Irvine, USA. tabotten@uci.edu
authors.forename: N D
authors.initials: ND
authors.lastname: Vaziri
authors.forename: Z
authors.initials: Z
authors.lastname: Ni
authors.forename: F
authors.initials: F
authors.lastname: Oveisi
mesh_terms: D000367:Age Factors; D000818:Animals; D001013:Aorta, Thoracic / Q000201:enzymology*; D001120:Arginine / Q000378:metabolism; D015153:Blotting, Western; D001835:Body Weight; D003404:Creatinine / Q000097:blood / Q000652:urine; D003627:Data Interpretation, Statistical; D004730:Endothelium, Vascular / Q000201:enzymology / Q000378:metabolism; D006400:Hematocrit; D006973:Hypertension / Q000209:etiology* / Q000378:metabolism; D066298:In Vitro Techniques; D007668:Kidney / Q000201:enzymology*; D008163:Luminescent Measurements; D008297:Male; D009566:Nitrates / Q000097:blood / Q000652:urine; D009569:Nitric Oxide / Q000378:metabolism* / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000032:analysis / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D009573:Nitrites / Q000097:blood / Q000652:urine; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D015854:Up-Regulation / Q000502:physiology*
chemical_list: D009566:Nitrates; D009573:Nitrites; D009569:Nitric Oxide; D001120:Arginine; D003404:Creatinine; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496318:Nos2 protein, rat; C496316:Nos3 protein, rat